ES2139012T3 - Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana. - Google Patents

Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.

Info

Publication number
ES2139012T3
ES2139012T3 ES93913627T ES93913627T ES2139012T3 ES 2139012 T3 ES2139012 T3 ES 2139012T3 ES 93913627 T ES93913627 T ES 93913627T ES 93913627 T ES93913627 T ES 93913627T ES 2139012 T3 ES2139012 T3 ES 2139012T3
Authority
ES
Spain
Prior art keywords
human
lymphocytes
specific
cytotoxic
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93913627T
Other languages
English (en)
Inventor
Cornelis Joseph Maria Melief
Wybe Martin Kast
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universiteit Leiden
Seed Capital Investments (SCI) BV
Original Assignee
Universiteit Leiden
Seed Capital Investments (SCI) BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universiteit Leiden, Seed Capital Investments (SCI) BV filed Critical Universiteit Leiden
Application granted granted Critical
Publication of ES2139012T3 publication Critical patent/ES2139012T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

UN PEPTIDO QUE COMPRENDE UNA SECUENCIA DE ACIDO AMINO DERIVADA DE LA PROTEINA P53 HUMANA, DE ACIDO AMINO, TIENE LA CAPACIDAD DE ENLAZAR A LA MOLECULA HUMANA CLASE I MHC. SU EMPLEO EN TRATAMIENTOS PROFILACTICOS O TERAPEUTICOS DE ENFERMEDADES TALES COMO LOS CANCERES HUMANOS QUE MUESTRAN UNA SOBRE-EXPRESION DE PROTEINA P53, Y SU EMPLEO EN LA INDUCCION DE CELULAS T ESPECIFICAS P53 PRIMARIAS QUE SE PUEDEN EMPLEAR EN TRATAMIENTOS TERAPEUTICOS. SU USO EN PRUEBAS Y TEST DE DIAGNOSTICO.
ES93913627T 1992-05-26 1993-05-18 Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana. Expired - Lifetime ES2139012T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP92201510 1992-05-26

Publications (1)

Publication Number Publication Date
ES2139012T3 true ES2139012T3 (es) 2000-02-01

Family

ID=8210629

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93913627T Expired - Lifetime ES2139012T3 (es) 1992-05-26 1993-05-18 Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.

Country Status (11)

Country Link
US (1) US5679641A (es)
EP (1) EP0643726B1 (es)
JP (2) JPH08501280A (es)
AT (1) ATE183514T1 (es)
AU (1) AU681853B2 (es)
CA (1) CA2136624A1 (es)
DE (1) DE69326064T2 (es)
DK (1) DK0643726T3 (es)
ES (1) ES2139012T3 (es)
GR (1) GR3031919T3 (es)
WO (1) WO1993024525A1 (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69333448D1 (en) * 1992-07-22 2004-04-15 Univ Princeton P53 impfstoff
FR2698367B1 (fr) * 1992-11-02 1995-02-17 Eurobio Lab Fragments de la protéine p53 et leurs utilisations dans la détection et le suivi d'états pathologiques.
CA2157510A1 (en) * 1993-03-05 1994-09-15 Howard M. Grey Hla-a2.1 binding peptides and their uses
SG49113A1 (en) * 1993-08-06 1998-05-18 Cytel Corp Methods for ex vivo therapy using peptide-loaded antigen presenting cells for the activation of ctl
FR2722207B1 (fr) * 1994-07-07 1996-09-27 Inst Nat Sante Rech Med Methode pour generer une population de cellules presentant a leur surface une forte densite d'un pepride exogene specifique associe azx molecules du cmh; population de cellules
EP0793501A4 (en) * 1994-12-14 2000-05-03 Scripps Research Inst IN VIVO ACTIVATION OF TUMOR SPECIFIC CYTOTOXIC T CELLS
US5925799A (en) * 1996-03-12 1999-07-20 Abb Lummus Global Inc. Catalytic distillation and hydrogenation of heavy unsaturates in an olefins plant
AU729406B2 (en) * 1996-03-28 2001-02-01 Johns Hopkins University, The Soluble divalent and multivalent heterodimeric analogs of proteins
US6458354B1 (en) 1996-03-28 2002-10-01 The Johns Hopkins University Molecular complexes which modify immune responses
US6218363B1 (en) * 1996-08-28 2001-04-17 Thomas Jefferson University MHC peptides and methods of use
SE9604581D0 (sv) * 1996-12-12 1996-12-12 Karolinska Innovations Ab An agent against cancer and virus infections
US6268411B1 (en) 1997-09-11 2001-07-31 The Johns Hopkins University Use of multivalent chimeric peptide-loaded, MHC/ig molecules to detect, activate or suppress antigen-specific T cell-dependent immune responses
EP1950223A3 (en) * 1998-03-09 2009-05-13 Zealand Pharma A/S Pharmacologically active peptide conjugates having a reduced tendency towards enzymatic hydrolysis
SE9801695D0 (sv) * 1998-05-14 1998-05-14 Karolinska Innovations Ab Inhibition of p53 function by a p53-derived peptide
EP1089757B1 (en) * 1998-06-17 2009-04-22 IDM Pharma, Inc. Hla binding peptides and their uses
EP1165144A2 (en) * 1999-03-15 2002-01-02 Introgen Therapeutics, Inc. Dendritic cells transduced with a wild-type self gene elicit potent antitumor immune responses
TW410377B (en) * 1999-06-17 2000-11-01 Taiwan Semiconductor Mfg Method of planarization and the apparatus of the same
WO2001018035A2 (en) * 1999-09-08 2001-03-15 Transgene S.A. Muc-1 derived peptides
FR2794368A1 (fr) * 1999-10-07 2000-12-08 Biovector Therapeutics Fragments proteiques polyepitopiques, leur obtention et leurs utilisations notamment en vaccination
AU2088701A (en) * 1999-12-10 2001-06-18 Epimmune, Inc. Inducing cellular immune responses to p53 using peptide and nucleic acid compositions
AU7524601A (en) * 2000-06-05 2001-12-17 Sunol Molecular Corp T cell receptor fusions and conjugates and methods of use thereof
DE10109855A1 (de) * 2001-03-01 2002-09-12 Stanislawski Thomas Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung
ES2307770T3 (es) * 2001-06-05 2008-12-01 Altor Bioscience Corporation Moleculas receptoras de las celulas t fijadoras de p53 y usos de las mismas.
WO2003006043A1 (en) 2001-07-10 2003-01-23 Massachusetts Institute Of Technology Surfactant peptide nanostructures, and uses thereof
CA2493081C (en) * 2002-07-12 2013-04-23 The Johns Hopkins University Reagents and methods for engaging unique clonotypic lymphocyte receptors
CN101291687A (zh) * 2005-05-12 2008-10-22 因特罗根治疗公司 用于癌症治疗的p53疫苗
AU2006289683A1 (en) * 2005-09-07 2007-03-15 Receptor Logic, Ltd. Antibodies as T cell receptor mimics, methods of production and uses thereof
US20110053849A1 (en) * 2006-08-17 2011-03-03 Salomon Amar Regulation of litaf modulated cytokine production by a novel p53 short peptide
US8889632B2 (en) 2007-01-31 2014-11-18 Dana-Farber Cancer Institute, Inc. Stabilized p53 peptides and uses thereof
JP5631201B2 (ja) 2007-03-28 2014-11-26 プレジデント アンド フェローズ オブ ハーバード カレッジ ステッチングされたポリペプチド
KR20180058866A (ko) 2010-08-13 2018-06-01 에일러론 테라퓨틱스 인코포레이티드 펩티도미메틱 거대고리
BR112014009418A2 (pt) 2011-10-18 2017-04-18 Aileron Therapeutics Inc macrociclos peptidomiméticos
CN112500466B (zh) 2012-02-15 2022-05-03 艾瑞朗医疗公司 拟肽大环化合物
WO2013123267A1 (en) 2012-02-15 2013-08-22 Aileron Therapeutics, Inc. Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles
MX2015005244A (es) 2012-11-01 2015-07-14 Aileron Therapeutics Inc Aminoacidos disustituidos y metodos de preparacion y el uso de los mismos.
AU2015320549A1 (en) 2014-09-24 2017-04-13 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
AU2015320545C1 (en) 2014-09-24 2020-05-14 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and formulations thereof
SG11201707750YA (en) 2015-03-20 2017-10-30 Aileron Therapeutics Inc Peptidomimetic macrocycles and uses thereof
CN108368161A (zh) 2015-09-10 2018-08-03 艾瑞朗医疗公司 作为mcl-1调节剂的拟肽大环化合物
CA3080274A1 (en) * 2017-09-29 2019-04-04 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods of isolating t cells having antigenic specificity for a p53 cancer-specific mutation
US11091522B2 (en) 2018-07-23 2021-08-17 Aileron Therapeutics, Inc. Peptidomimetic macrocycles and uses thereof
WO2021087840A1 (zh) * 2019-11-07 2021-05-14 武汉华大吉诺因生物科技有限公司 肿瘤免疫治疗多肽及其应用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NO312681B1 (no) * 1990-08-24 2002-06-17 Univ California Fremgangsmåte for fremstilling av en farmasöytisk blanding med suppresiv virkning/aktivitet

Also Published As

Publication number Publication date
EP0643726A1 (en) 1995-03-22
WO1993024525A1 (en) 1993-12-09
US5679641A (en) 1997-10-21
JPH08501280A (ja) 1996-02-13
DE69326064T2 (de) 2000-05-25
ATE183514T1 (de) 1999-09-15
DK0643726T3 (da) 2000-03-20
DE69326064D1 (de) 1999-09-23
GR3031919T3 (en) 2000-03-31
CA2136624A1 (en) 1993-12-09
AU681853B2 (en) 1997-09-11
JP2004123708A (ja) 2004-04-22
EP0643726B1 (en) 1999-08-18
AU4359193A (en) 1993-12-30

Similar Documents

Publication Publication Date Title
ES2139012T3 (es) Peptidos de la proteina p53 humana destinados para ser utilizados en composiciones que inducen una reaccion en los linfocitos t humanos, y linfocitos t citotoxicos especificos de la proteina p53 humana.
ES2075050T3 (es) Peptidos que tienen actividad cooperadora de celulas t.
ES2205132T3 (es) Subunidad catalitica de la telomerasa humana.
EA200501206A1 (ru) Производные от сурвивина пептиды и их применение
DK0719340T3 (da) Klonet glutaminsyre-decarboxylase
AR006188A1 (es) "composicion farmaceutica para inhibir la actividad de serinproteasa, metodo in vitro para inhibir la actividad de serinproteasa y metodo para preparar dicha composicion".
DE3751470D1 (de) Pentigetide zur Behandlung von nicht-IgE-vermittelten entzündlichen Erkrankungen.
EA199800946A1 (ru) Концентрированный препарат антител
EA199900486A1 (ru) Применение сфингомиелиназы для повышения уровней церамидов в коже и слизистых оболочках, а также содержащие ее дерматологические и косметические композиции, которые удобны для местного применения
TR200103560T2 (tr) Göğüs kanserinin teşhis ve tedavisi için bileşimler ve bunların kullanımı
BG100771A (bg) Хематопоетичен протеин и материали и методи за неговото получаване
DK0810870T3 (da) Isolerede, MAGE-2-afledte tumorafstødelsesantigenpræcurserpeptider og anvendelse heraf
ATE235510T1 (de) Integrinbindendes peptid und dessen verwendung
BR9509172A (pt) Proteina de via de complemento nativa sequéncia de dna construção de dna conjugado uso de uma proteína processo para reduzir proteina de via de complemento em um mamifero e formulação farmacéutica
MX9702666A (es) Nuevos peptidos con efectos inmunoreguladores.
ATE296312T1 (de) Metalkomplexbildner
ATE326981T1 (de) Isolierte peptide die aminosäuresequenzen von ny- eso-1 entsprechen und an mhc-klasse i und mhc klasse ii moleküle binden, und deren verwendungen
ES2141249T3 (es) Procedimiento para la identificacion de celulas humanas y animales que presentan la capacidad para una proliferacion ilimitada o para una formacion de tumores.
DK0707473T3 (da) Orale farmaceutiske præparater omfattende et protein eller et peptid, et antistof og polymerkugler
DK199881A (da) Analogifremgangsmaade til fremstilling af pharmakologisk aktive peptider
ATE336579T1 (de) Isolierte mhc-klasse ii-bindende peptide, und deren verwendung
BR9608626A (pt) Peptédeo preparação farmacéutica e uso de um peptídeo
TR199801769T2 (xx) D���k reg�lasyona diren�li C3 d�n��t�r�c�ler.
BR0012704A (pt) Anticorpos antitumor, proteìnas e usos dos mesmos
TR199700842T1 (xx) �nsan DNase I Varyantlar�.

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 643726

Country of ref document: ES